Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

• Published in: Current Alzheimer research Vol. 14; no. 11; p. 1164
• Main Authors: Ahmad, Javed, Akhter, Sohail, Rizwanullah, Md, Khan, Mohammad Ahmed, Pigeon, Lucie, Addo, Richard T, Greig, Nigel H, Midoux, Patrick, Pichon, Chantal, Kamal, Mohammad Amjad
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01-01-2017
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - physiopathology; Alzheimer Disease - therapy; Animals; Disease Management; Humans; Theranostic Nanomedicine; blood brain barrier; diagnosis; nanoparticles; theranostic; Alzheimer's disease; nanomedicines
• ISSN: 1875-5828
• DOI: 10.2174/1567205014666170508121031

Alzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now, anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome required drug targeting across the blood-brain barrier (BBB) to the central nervous system (CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and theranostics offer highly sensitive molecular detection, effective drug targeting and their combination. Over the past decade, significant works have been done in this area and we have seen very remarkable outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have successfully been investigated against AD.
This paper discussed the role of nanoparticles in early detection of AD, effective drug targeting to brain and theranostic (diagnosis and therapy) approaches in AD's management.